Triple Point Ventures London, GB
Triple Point Ventures is the venture capital arm of the Triple Point Group, a London-based investment manager founded in 2004. Launched in 2018, it invests in early-stage B2B software businesses across sectors including fintech, data, AI, healthcare, vertical SaaS, and energy.
Founded —
Type Venture capital 1 Triple Point Venture VCT plc — — Continuinglistedvehicle, notconventionalfundclose. NetassetsGBP111.768mat2026-02-28; FYsubscriptionsGBP31.6mgross; approved2026-06-29. LatestSept1 2026offerGBP10mtarget+10moverallotmentmax20m scheduledJuly30 2027close; amounts distinctfromcommitments.
SHOW MORE
— — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – — — — – —
SHOW MORE
$— 2026-02-03 Lateral Triple Point Ventures $— 2026 Handshake Solutions Triple Point Ventures $— 2026 Asterix Health Triple Point Ventures $— 2026 Infrawatch Portfolio Ventures , Triple Point Ventures $30M 2025-06-03 Treefera Notion Capital , AlbionVC , Triple Point Ventures , Paul Lehair , Patrick Norris $6M 2024-08-15 Trumpet AlbionVC , Triple Point Ventures , Paul Lehair $8M 2024-06-10 Visibly Creandum , Hanel Baveja , Seedcamp , Brighteye Ventures , Triple Point Ventures $— 2024-03-01 Heat Geek Triple Point Ventures $15M 2023-11-29 Modo Energy General Catalyst , MMC Ventures , Triple Point Ventures , Simon Menashy £8M 2023-11-21 Seechange Technologies Triple Point Ventures $6M 2023-06-30 Fertifa Notion Capital , Triple Point Ventures , Speedinvest $— 2023-05-17 Nory Triple Point Ventures $— 2023-03 Foodji Triple Point Ventures $— 2023-02-20 Aerocloud Triple Point Ventures $— 2023-02-02 Superlayer Notion Capital , Triple Point Ventures $— 2023-01-10 Creative Fabrica Felix Capital , Triple Point Ventures $— 2023 Foodji Triple Point Ventures $— 2023 Springpod Triple Point Ventures $— 2023 Scan.com Triple Point Ventures $— 2022-09-22 The Electric Car Scheme Triple Point Ventures $— 2022-07-20 Veremark Triple Point Ventures $— 2022-05-25 Crowd Data Systems Triple Point Ventures , Portfolio Ventures $— 2022-05-12 MyMynd Triple Point Ventures $80M 2022-01-26 Cowboy HCVC , Triple Point Ventures $— 2022 Konfir Triple Point Ventures $— 2022 Crowd Data Systems Triple Point Ventures , Portfolio Ventures $10M 2021-12-07 Learnerbly Frontline Ventures , Primary Venture Partners , Triple Point Ventures $3M 2021-11-18 Pixie Triple Point Ventures , MMC Ventures $— 2021-08-12 Ryde Triple Point Ventures $— 2021-07-06 StepEx Triple Point Ventures $70M 2021-06-30 Ably MMC Ventures , Triple Point Ventures £1M 2021-03-24 GripAble Triple Point Ventures $5M 2021-02-24 Patch Triple Point Ventures , Jeff Jordan $— 2020-05-07 Countingup Triple Point Ventures $32M 2019-08-15 Nurx Y Combinator , Kleiner Perkins , Union Square Ventures , Dreamers VC , Triple Point Ventures $— Unknown date 3Dctrl Triple Point Ventures $— Unknown date GripAble Triple Point Ventures $— Unknown date Cyacomb Triple Point Ventures $— Unknown date We Are Digital Triple Point Ventures $— Unknown date Aptem Triple Point Ventures $— Unknown date Konfir Triple Point Ventures $— Unknown date Knok Triple Point Ventures $— Unknown date Sonicjobs Triple Point Ventures $— Unknown date Kamma Triple Point Ventures $— Unknown date Semble Triple Point Ventures $— 2026-07-14 Prolo Portfolio Ventures , Triple Point Ventures £8M 2023-11-21 SeeChange Triple Point Ventures , Crane Venture Partners , Portfolio Ventures £6M 2022-11-29 Biorelate Triple Point Ventures $— 2021-09-28 Heydoc Triple Point Ventures $11M 2020-03-18 Quit Genius Y Combinator , Burda Principal Investments , Octopus Ventures , StartUp Health , Triple Point Ventures $— Unknown date Skin Analytics Triple Point Ventures $— Unknown date NatureMetrics Triple Point Ventures $— Unknown date Bow & Drape Triple Point Ventures $— Unknown date Exate Technology Triple Point Ventures $— Unknown date Aerocloud Systems Triple Point Ventures $— Unknown date Grokr Triple Point Ventures
SHOW MORE
team@apexlogos.ai · 13 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities.
Capital, vehicles and latest-known fundraising
| Measure | Amount and status | Date and supporting source |
|---|---|---|
| Triple Point Venture VCT plc net assets | **£111.768 million**; measured balance-sheet net assets, not a closed-end fund commitment | At 28 February 2026; annual report approved 29 June 2026, financial summary p.3 and balance sheet p.79. [Official 2026 annual report](https://www.triplepoint.co.uk/wp-content/uploads/2026/06/Triple-Point-Venture-VCT-Annual-Report-2026.pdf ) |
| VCT subscriptions raised in financial year | **£31.6 million gross proceeds** from issued Venture Shares; actual fundraising during the year, not the size of a new fund | Year ended 28 February 2026; same annual report, p.3. |
| Latest-known new VCT offer | **£10 million target**, with **£10 million additional over-allotment capacity**; maximum £20 million offer. No verified final close as of this research | Prospectus dated 1 September 2026; offer opens 1 September 2026, scheduled to close 30 July 2027 unless closed earlier or extended. [Official 2026/27 prospectus](https://www.triplepoint.co.uk/wp-content/uploads/2026/09/TPV-VCT-Prospectus-26-27.pdf ), pp.9–10, 17 |
| Prior offer | Initially £10 million plus £20 million over-allotment; subsequently increased to **£45 million capacity** (base £10 million plus £35 million over-allotment). This is offer capacity, not evidence that £45 million closed | Initial prospectus 5 September 2025; supplementary prospectus 26 February 2026 describes increase announced 18 February. [Official initial prospectus](https://www.triplepoint.co.uk/wp-content/uploads/2025/05/Triple-Point-Venture-VCT-Prospectus-September-2025.pdf ); [supplementary prospectus reproduced by Publicnow/MarketScreener](https://www.marketscreener.com/news/triple-point-venture-vct-supplementary-prospectus-ce7e5cdcd18cf722 ) |
These are sterling figures. The VCT is a continuing listed vehicle, so an annual share offer should not be entered as a conventional “Fund II” close. No aggregate firm venture AUM or original Impact EIS fund size was verified. The wider group's AUM would be a different measure.
Funds recorded in Adex after this review:
| Fund | Disclosed amount | Announcement / filing date |
| --- | --- | --- |
| Triple Point Venture VCT plc | Undisclosed / unverified | Unknown | SHOW MORE
team@apexlogos.ai · 14 hours ago
Match research 2026-10-06 / GoldiTriplePointVentures / sha256:fa3cce5d0610c3a58c53beefd08feeaa402f13984f260600d5f947f29a197f84 / part 2 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
| **GripAble** | Sensor hardware, movement assessment and gamified rehabilitation software; medical-device exposure | Official firm portfolio lists **2019**; 2021 follow-on evidence below provides named Triple Point attribution. Treat medical devices as a distinct category from pure software. |
## Neurotechnology and adjacent investments
**GripAble: verified neurorehabilitation investment, broader neurotech definition.** Its smart hand controller connects to an app to assess and train movement and grip in patients with upper-limb impairments, including after stroke. Its origin was neuroscientist Paul Rinne's work with stroke therapy teams; the official story describes use in neurological and orthopaedic rehabilitation. It does not establish EEG, direct neural sensing, implanted devices or stimulation. [Official GripAble story, undated, accessed 2026-10-06](https://gripable.co/our-story/ ). Its resources include a 2016 neurorehabilitation paper and 2021 stroke exergaming work, supporting the neurological use case rather than just generic fitness. [Official research resources, undated, accessed 2026-10-06](https://gripable.co/us/resources/ ).
A **£1.6 million pre-Series A/seed follow-on**, reported **24 March 2021**, was led by Triple Point Venture Fund with Oxford Technology Fund and Imperial College Innovation Fund. The report quotes Triple Point's head of impact investment describing its original 2019 funding; this is consistent with the current official portfolio. [UKTN, 24 March 2021](https://www.uktech.news/news/london-startup-gripable-funding-20210324 ). A [public company/CEO announcement](https://www.linkedin.com/posts/paul-rinne-22174061_gripable-secures-16-million-seed-follow-activity-6780548613232697344-ONll ) also states the £1.6 million close and Triple Point leadership; indexed relative post age is not a precise publication date. Exact legal fund allocation remains unresolved.
**No verified investment in direct neural recording, brain-computer interfaces or neural stimulation found in the sources checked.** If the Adex neurotech classification excludes neurorehabilitation without direct neural signals, record GripAble as adjacent neurorehabilitation and use: “No verified neurotech investment found in the sources checked” for that stricter definition.
Other distinctions: Biorelate is general biomedical discovery infrastructure, not evidence of a specific neuroscience drug program. Skin Analytics is dermatology AI; Scan.com is imaging access rather than a demonstrated brain technology. Official portfolio/news list Paloma Health as autism/ADHD diagnosis services, Pelago as addiction healthcare, and BIOS Life as cancer surveillance. These are not automatically direct neurotechnology. **BIOS Life is not BIOS Health**, the similarly named neural-interface business. [Official news listing, accessed 2026-10-06; Paloma article dated 29 July 2025 and BIOS Life article 14 August 2026](https://www.triplepoint.vc/news/ ).
## Attribution conflicts, missing information and later Adex review
1. **Wispr AI needs correction review.** Adex attributes its 24 October 2022 financing to this firm. The company's original announcement names **Triple Point Capital**, alongside Neo and MVP, in **$10 million equity and debt Seed II**. It calls Wispr a neurotechnology company, but the evidence does not name UK Triple Point Ventures; exclude it from verified neurotech history here. [Company-issued PRNewswire announcement, 24 October 2022](https://www.prnewswire.com/news-releases/wispr-raises-another-10m-to-build-a-more-natural-way-to-interact-with-technology-301657331.html ).
2. **Planet A Foods requires the same attribution check.** Its original **1 February 2024** $15.4 million Series A announcement names **Triple Point Capital / TriplePoint Capital**, not Triple Point Ventures. Do not count fermentation technology as this firm's verified deep-tech investment. [Official investee announcement](https://planet-a-foods.com/press/articles/mzsly86l1geymdpzdccijeaz/planet-a-foods-series-a ).
3. **Bow & Drape** is another suspect baseline association: Forbes' January 2014 reporting names Triple Point Capital, and the date predates the UK venture strategy. [Forbes, 30 January 2014, updated 1 February 2014](https://www.forbes.com/sites/clareoconnor/2014/01/30/zappos-mogul-tony-hsiehs-latest-bet-high-tech-fashion/ ). Grokr's 2012 baseline record also warrants a separate investor-identity review; it was not verified here.
4. **GripAble Series A misattribution risk.** The baseline attaches an $11 million Series A link to this firm. Parkwalk's **11 April 2022** announcement describes a round led by IP Group with Parkwalk and does not name Triple Point. Existing ownership is not participation in each later round. Keep the independently verified 2019/2021 history; mark 2022 Triple Point participation unconfirmed. [Official co-investor announcement](https://parkwalk.vc/article/gripable-raises-11m-series-a-round/ ).
5. Merge/review duplicate Adex company identities for SeeChange/Seechange Technologies and Aerocloud/Aerocloud Systems only after company-ID validation. A duplicate name alone is not sufficient for a database change.
6. Proposed research-backed review values: current check ceiling £5 million; current stated stages pre-seed/seed, historical supported Series A; VCT net assets £111.768 million at 28 February 2026; latest-known offer target £10 million plus £10 million capacity dated 1 September 2026. Preserve the metric and date alongside each amount. No closed conventional VC fund size or aggregate venture AUM verified.
7. This report does not exhaustively reverify every ordinary software holding or all eleven undated team roles. Full original Impact EIS size, exact GripAble/NatureMetrics/Skin Analytics vehicle allocation, current minimum check and neurotech definition remain gaps. Current website strategy differs from older profile language and should carry an access date.
All linked sources were accessed 2026-10-06. Publication dates are recorded where available; undated portfolio pages verify firm association but not exact transaction terms. No source establishes an absence of unpublicized investments. SHOW MORE
team@apexlogos.ai · 14 hours ago
Match research 2026-10-06 / GoldiTriplePointVentures / sha256:fa3cce5d0610c3a58c53beefd08feeaa402f13984f260600d5f947f29a197f84 / part 1 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
# Triple Point Ventures — GoldiTriplePointVentures
- Exact Adex ID: `GoldiTriplePointVentures`
- Canonical Adex page: https://adex.page/firms/GoldiTriplePointVentures
- Research date: 2026-10-06
- Status: complete research report; no Adex or database edits made.
## Identity and assessment
Triple Point Ventures is the London venture strategy of Triple Point Investment Management. Its current website targets founders with a UK footprint at pre-seed and seed, across fintech, health, climate, data and AI, and says it likes to lead rounds with tickets up to **£5 million**. This is a check ceiling, not fund size. The website footer identifies the Triple Point Group and its regulated UK investment manager. [Official firm website, undated, accessed 2026-10-06](https://www.triplepoint.vc/ ).
It has credible deep-tech exposure through scientific data, environmental DNA and medical devices alongside a predominantly B2B software portfolio. GripAble is verified neurorehabilitation exposure, with an explicit distinction from brain interfaces. A baseline Wispr investment cannot be attributed to this firm: the original announcement names **Triple Point Capital**. Do not merge the UK venture firm with the similarly named US investor.
## Starting evidence: Adex and NFX Signal
The saved exact-ID snapshot, `data/research/_sources/GoldiTriplePointVentures.adex.json`, was retrieved on 2026-10-06 through read-only MCP Search. It describes a venture arm launched in 2018 within a group founded in 2004. Its investor profile has null minimum, maximum and sweet-spot checks. It lists eleven investor roles, including Ian McLennan, Seb Wallace, Jamie Tomalin, Chris Lascelles and Sam Stone, but does not date them; they should not all be assumed current. Prior investment records include SeeChange, Biorelate, GripAble, Wispr AI, Planet A Foods and Bow & Drape, plus several duplicate company spellings. Some sources are only Goldi home-page links and some dates precede the strategy launch. These are leads rather than independent verification.
[NFX Signal: Triple Point](https://signal.nfx.com/firms/triple-point ) was directly opened on 2026-10-06. Its readable page confirms only the name and London location; the team heading yielded no visible people, fund, stage or check-size detail. Signal therefore provides an identity cross-check, not independent investment validation. The URL matches the saved baseline.
## Capital, vehicles and latest-known fundraising
| Measure | Amount and status | Date and supporting source |
|---|---|---|
| Triple Point Venture VCT plc net assets | **£111.768 million**; measured balance-sheet net assets, not a closed-end fund commitment | At 28 February 2026; annual report approved 29 June 2026, financial summary p.3 and balance sheet p.79. [Official 2026 annual report](https://www.triplepoint.co.uk/wp-content/uploads/2026/06/Triple-Point-Venture-VCT-Annual-Report-2026.pdf ) |
| VCT subscriptions raised in financial year | **£31.6 million gross proceeds** from issued Venture Shares; actual fundraising during the year, not the size of a new fund | Year ended 28 February 2026; same annual report, p.3. |
| Latest-known new VCT offer | **£10 million target**, with **£10 million additional over-allotment capacity**; maximum £20 million offer. No verified final close as of this research | Prospectus dated 1 September 2026; offer opens 1 September 2026, scheduled to close 30 July 2027 unless closed earlier or extended. [Official 2026/27 prospectus](https://www.triplepoint.co.uk/wp-content/uploads/2026/09/TPV-VCT-Prospectus-26-27.pdf ), pp.9–10, 17 |
| Prior offer | Initially £10 million plus £20 million over-allotment; subsequently increased to **£45 million capacity** (base £10 million plus £35 million over-allotment). This is offer capacity, not evidence that £45 million closed | Initial prospectus 5 September 2025; supplementary prospectus 26 February 2026 describes increase announced 18 February. [Official initial prospectus](https://www.triplepoint.co.uk/wp-content/uploads/2025/05/Triple-Point-Venture-VCT-Prospectus-September-2025.pdf ); [supplementary prospectus reproduced by Publicnow/MarketScreener](https://www.marketscreener.com/news/triple-point-venture-vct-supplementary-prospectus-ce7e5cdcd18cf722 ) |
These are sterling figures. The VCT is a continuing listed vehicle, so an annual share offer should not be entered as a conventional “Fund II” close. No aggregate firm venture AUM or original Impact EIS fund size was verified. The wider group's AUM would be a different measure.
## Investment stages and mandate
Current primary website: **pre-seed and seed**, UK footprint, cross-sector, with a preference to lead. A March 2025 Innovate UK investor profile gives **pre-seed, seed and Series A** and describes two mandates: an already fully deployed **Triple Point Impact EIS** and an active venture VCT focused on fast-growing B2B software. This is dated evidence rather than proof that the EIS currently accepts new capital. [UKRI/Innovate UK March 2025 investor profiles, p.171](https://www.ukri.org/wp-content/uploads/2023/03/080525_UKRI_Investor-Profiles-Document_March-2025_TW_D3_Part2.pdf ).
Historical Series A participation is supported by Biorelate below. It does not mean all initial investments now target Series A. The homepage's portfolio success banners show later financing secured by investees; those round totals do not establish Triple Point's participation or check size in the displayed later round.
## Named previous deep-tech investments
Deep-tech classifications below are analytical judgments based on the technology described, not assertions that all AI or software is deep tech.
| Company | Technology and classification | Firm attribution and dated investment evidence |
|---|---|---|
| **SeeChange Technologies / SeeChange** | Computer vision AI for retail checkout and loss prevention; a technical vision-inference product rather than ordinary workflow SaaS. Applied deep-tech exposure, with research intensity not independently quantified | Investee announces a **closed £8 million (US$10 million) seed extension**, **21 November 2023**, co-led by Crane Venture Partners and **Triple Point Ventures**. This is whole-round size. [Official investee announcement](https://seechange.com/seechange-technologies-raises-8m-in-seed-extension-funding-to-transform-global-retail-with-vision-ai/ ) |
| **Biorelate** | Proprietary NLP, machine learning and biomedical knowledge curation supporting drug discovery; strongest evidence of scientific deep-tech software | Official Triple Point VCT 2011 report describes the technology and records first investment **22 November 2022**, cost **£999,998**, in that specific managed vehicle. This vehicle attribution matters: do not assume every portfolio holding is in Venture VCT plc. [Official VCT 2011 annual report, 2023, Biorelate case study](https://www.triplepoint.co.uk/wp-content/uploads/2025/07/Triple-Point-VCT-2011-Annual-Report-2023.pdf ). A **£6.5 million Series A** reported 29 November 2022 was led by Maven and YFM with Triple Point participating, corroborated by the investee's public announcement [via CEO/company LinkedIn post](https://www.linkedin.com/posts/daniel-jamieson-8498a33a_im-delighted-to-share-that-biorelate-have-activity-7004007527675764736-NcIJ ) and [dated reporting, updated 30 November 2022](https://www.thesaasnews.com/news/biorelate-raises-6-5-million-in-series-a/ ). Triple Point was not the lead in that round. |
| **NatureMetrics** | Environmental DNA sampling and analysis for biodiversity measurement; scientific biotechnology and data infrastructure | Official Triple Point portfolio explicitly lists NatureMetrics with **2019** as its investment year. Exact date, vehicle and check were not established. [Firm portfolio, undated, accessed 2026-10-06](https://www.triplepoint.vc/portfolio/ ). [Investee technology website, undated, accessed 2026-10-06](https://naturemetrics.com/ ) supports the environmental DNA rationale. Do not infer participation in later NatureMetrics rounds. |
| **Skin Analytics** | AI medical device DERM for skin cancer decisions; regulated clinical computer vision | Same official firm portfolio lists Skin Analytics with **2018**. No precise original round or vehicle verified. [Investee announcement dated 16 April 2025](https://skin-analytics.com/news/funding/series-b-15million-funding/ ) describes the technology and its £15 million Series B led by Intrepid Growth Partners; that announcement does **not** establish Triple Point participation in the 2025 round. | SHOW MORE
team@apexlogos.ai · 23 days ago
MATCH 
Portfolio Ventures
Infrawatch$— · 2026
Crowd Data Systems$— · 2022-05-25
MMC Ventures
Modo Energy$15M · 2023-11-29
Pixie$3M · 2021-11-18
Ably$70M · 2021-06-30
Notion Capital
Treefera$30M · 2025-06-03
Fertifa$6M · 2023-06-30
Superlayer$— · 2023-02-02
Y Combinator
Nurx$32M · 2019-08-15
Brighteye Ventures
Visibly$8M · 2024-06-10
Crane Venture Partners
Felix Capital
Creative Fabrica$— · 2023-01-10
Frontline Ventures
Learnerbly$10M · 2021-12-07
General Catalyst
Hanel Baveja
Jeff Jordan
Patch$5M · 2021-02-24
Patrick Norris
Primary Venture Partners
Simon Menashy
Speedinvest
